​

RenovoRx Stock (NASDAQ:RNXT)

ForecastOwnershipFinancialsChart
RenovoRx by TradingView

Previous Close

$0.77

52W Range

$0.75 - $1.69

50D Avg

$1.02

200D Avg

$1.13

Market Cap

$30.87M

Avg Vol (3M)

$146.57K

Beta

1.11

Div Yield

-

RNXT Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Aug 26, 2021

Website

RNXT Performance

RNXT Financial Summary

Dec 24Dec 23Dec 22
Revenue$43.00K--
Operating Income$-10.97M$-11.40M$-9.95M
Net Income$-8.81M$-10.23M$-9.77M
EBITDA$-10.97M$-11.39M$-9.94M
Basic EPS$-0.04$-0.99$-1.08
Diluted EPS$-0.04$-0.99$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
LGVNLongeveron Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc.
NTRBNutriband Inc.
ADILAdial Pharmaceuticals, Inc.
TPSTTempest Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
MNPRMonopar Therapeutics Inc.
SABSSAB Biotherapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
KTTAPasithea Therapeutics Corp.
IKNAIkena Oncology, Inc.